Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study

Published:November 26, 2022DOI:


      • Phase-III-trials have shown that dupilumab in severe asthma (SA) is effective and safe. Real-world data on clinical efficacy and safety is limited.
      • This real-world study indicates that dupilumab in SA leads to less asthma exacerbations, decreased oral corticosteroid use, and better asthma control.
      • Most benefits were seen in patients with high eosinophils and FeNO. Dupilumab also proved a safe treatment with infrequent, mild side effects.
      • Therefore, this study implies that the results of the phase-III-trials translate well to daily clinical practice.



      Dupilumab as add-on treatment for severe uncontrolled asthma (SA) has shown to be effective and safe by phase-III-trials. Real-world data on clinical efficacy and safety is limited.


      We aim to investigate the efficacy and safety of dupilumab as add-on therapy for SA in a real-world cohort.

      Material and methods

      The primary endpoint was annually exacerbation-rate (AER). Secondary outcomes were maintenance oral corticosteroid (mOCS) dependency, asthma control (ACQ-5), pulmonary function (FEV1), quality of life (AQLQ) and frequency of reported adverse events (AEs).


      Overall, 148 patients were included. Median AER [IQR] reduced from 4.00 [2.00–5.00] at baseline to 1.00 [0.00–2.00] at 12 months (p < 0.001). mOCS-dependency reduced from 39.9% of the patients at baseline, to 20.3% at 6 months and to 14.9% at 12 months (p < 0.001). Median ACQ improved from 3.00 [2.00–3.80] at baseline to 1.80 [0.60–2.95] after 6 months and to 1.40 [0.20–2.60] after 12 months (p < 0.001). Median FEV1 (L) improved from 2.21 [1.58–2.85] to 2.50 [2.00–3.06] at 6 months and to 2.51 [1.88–3.04] after 12 months (p < 0.001). The outcomes improved most in subgroups with high eosinophils (≥300/μL) or FeNO (≥50 ppb) at baseline. AEs were reported by 45.3% (67/148), of which headache was most frequent.


      This study indicates that dupilumab as add-on therapy for SA is associated with significant improvements in exacerbation-rate, mOCS-dependency, asthma control, pulmonary function, and quality of life. These results are in line with those of previous phase-III-trials.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Respiratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Global Initiative for Asthma
        Global strategy for asthma management and prevention.
        (Available at:)
        Date: 2021
        Date accessed: September 18, 2022
        • Nielen M.
        • Hek K.
        Jaarcijfers aandoeningen - huisartsenregistraties.
        (Available at:)
        • Hekking P.W.
        • Wener R.R.
        • Amelink M.
        • Zwinderman A.H.
        • Bouvy M.L.
        • Bel E.H.
        The prevalence of severe refractory asthma.
        J. Allergy Clin. Immunol. 2015; 135: 896-902
        • Frøssing L.
        • Silberbrandt A.
        • Von Bülow A.
        • Backer V.
        • Porsbjerg C.
        The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma.
        J. Allergy Clin. Immunol. Pract. 2021; 9: 1267-1275
        • Oishi K.
        • Hirano T.
        • Matsuda K.
        • Hamada K.
        • Uehara S.
        • Suetake R.
        • Yamaji Y.
        • Asami-Noyama M.
        • Edakuni N.
        • Matsunaga K.
        The prevalence and clinical characteristics of T2-high and T2-low endotype of severe uncontrolled asthma distinguished by combining popular type-2 biomarkers.
        Eur. Respir. J. 2019; 54: 2749
        • Agache I.
        • Beltran J.
        • Akdis C.
        • et al.
        Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
        Allergy. 2020; 75: 1023-1042
        • Castro M.
        • Corren J.
        • Pavord I.D.
        • et al.
        Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.
        N. Engl. J. Med. 2018; 378: 2486-2496
        • Wenzel S.
        • Castro M.
        • Corren J.
        • et al.
        Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
        Lancet. 2016; 388: 31-44
        • Rabe K.F.
        • Nair P.
        • Brusselle G.
        • et al.
        Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma.
        N. Engl. J. Med. 2018; 378: 2475-2485
        • Richards L.B.
        • van Bragt J.J.M.H.
        • Aarab R.
        • et al.
        Treatment eligibility of real-life mepolizumab-treated severe asthma patients [published correction appears in J allergy clin immunol pract. 2021 jan;9(1):604].
        J. Allergy Clin. Immunol. Pract. 2020; 8 (2999-3008.e1)
        • Bousquet J.
        • Humbert M.
        • Gibson P.G.
        • et al.
        Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies.
        J. Allergy Clin. Immunol. Pract. 2021; 9: 2702-2714
        • Israel E.
        • Canonica G.W.
        • Brusselle G.
        • et al.
        Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review [published online ahead of print, 2021 Dec 24].
        J. Asthma. 2021; : 1-17
        • Menzella F.
        • Bargagli E.
        • Aliani M.
        • et al.
        ChAracterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
        Respir. Res. 2022; 23 (Published 2022 Feb 19): 36
        • Kavanagh J.E.
        • Hearn A.P.
        • Dhariwal J.
        • et al.
        Real-world effectiveness of benralizumab in severe eosinophilic asthma.
        Chest. 2021; 159: 496-506
        • Pérez de Llano L.A.
        • Cosío B.G.
        • Lobato Astiárraga I.
        • et al.
        Asthma control in patients with severe eosinophilic asthma treated with reslizumab: Spanish real-life data.
        J. Asthma Allergy. 2022; 15 (Published 2022 Jan 14): 79-88
        • Yılmaz İ.
        Biologics for oral corticosteroid-dependent asthma.
        Allergy Asthma Proc. 2020; 41: 151-157
        • Heffler E.
        • Paoletti G.
        • Giorgis V.
        • et al.
        Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
        Expet Rev. Clin. Immunol. 2019; 15: 951-958
        • von Elm E.
        • Altman D.G.
        • Egger M.
        • Pocock S.J.
        • Gøtzsche P.C.
        • Vandenbroucke J.P.
        • Strobe Initiative
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies.
        Lancet. 2007 Oct 20; 370: 1453-1457
        • Juniper E.F.
        • Svensson K.
        • Mörk A.C.
        • Ståhl E.
        Measurement properties and interpretation of three shortened versions of the asthma control questionnaire.
        Respir. Med. 2005; 99: 553-558
        • Stanojevic S.
        • Kaminsky D.A.
        • Miller M.R.
        • et al.
        ERS/ATS technical standard on interpretive strategies for routine lung function tests.
        Eur. Respir. J. 2022; 602101499
        • Dupin C.
        • Belhadi D.
        • Guilleminault L.
        • et al.
        Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort.
        Clin. Exp. Allergy. 2020; 50: 789-798
        • Renner A.
        • Marth K.
        • Patocka K.
        • Idzko M.
        • Pohl W.
        Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics.
        Immun Inflamm Dis. 2021 Sep; 9: 624-627
        • Campisi R.
        • Crimi C.
        • Nolasco S.
        • et al.
        Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program.
        J. Asthma Allergy. 2021; 14: 575-583